Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
Cancer stem cells (CSCs) have attracted a lot of interest in the field of cancer research in recent years. Lung CSCs share many characteristics with the normal pluripotent stem cells, such as self-renewal and multi-potent abilities. Identification of normal adult lung stem cells and their response to injury has led us to the lung cancer stem cells, partially based on the knowledge that lung CSCs as well as the normal lung stem cells share similar markers and/or location in the airway tree. Several studies have identified CD133, CD44, ALDH (aldehyde dehydrogenase) and ABCG2 (ATP-binding cassette sub-family G member 2) as lung cancer stem cell markers, all of which are validated CSC markers in multiple other cancer types as well. Embryogenesis signaling pathways, such as the hedgehog, wnt and notch pathways has also been implicated as determinants of lung CSC phenotype. With the central role of CSCs in tumor recurrence, metastasis and drug-resistance, targeting CSC markers and/or signaling pathways to eradicate lung cancer and enhance patient outcome is an attractive approach. This review summarizes our current understanding of CSC markers and signaling pathways in lung cancer.
Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi